Technology Overview

Currently, management of chronic degenerative conditions are limited to general or targeted suppression of the immune system. The purpose of these therapies is to arrest the immune system sufficiently to decrease the symptoms of a disease without completely destroying the body’s ability to defend itself from infection and cancer.

Nonetheless, the result is often a modest reduction or delay in chronic symptoms with significant potential side effects such as opportunistic infections and the development of cancer. Sekris is commercializing a next generation platform technology, which reprograms the immune system and induces immune tolerance to self and transplanted tissues.